

OTIP & JC98-000000
JUL 19 2004

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 TRADEMARK		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: July 19, 2004 (use as many sheets as necessary)		Application Number	10/734,638
		Filing Date	12/15/2003
		First Named Inventor	Philippe ROUANET et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 1 of 1	Attorney Docket Number	029488-0113	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AM	A1	4,973,755		Heumann Pharma GmbH & Co.	11/27/1990	
AM	A2	4,919,937		Pierre MAUVAIS-JARVIS et al.	4/24/1990	
AM	A3	5,904,930		Hexal AG Fischer et al.	5/18/1999	
AM	A4	5,945,109		s.w. Patentverwertungs Ges.m.b.H.	8/31/1999	
				Schmidt et al.		

7/3/06
3

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
AM	A5	International Search Report		
AM	A6	Pierre MAUVAIS-JARVIS et al., "trans-4-Hydroxytamoxifen Concentration and Metabolism after Local Percutaneous Administration to Human Breast", Cancer Research, Vol. 46, 3/1986, pp. 1521-1525.		
AM	A7	F. KUTTENN et al., "Principe de l'administration percutanée des antiestrogènes en pathologie mammaire", Contracept. Fétil. Sex. 1991, Vol. 19, No. 2, pp. 165-171.		
AM	A8	I. Simony-Lafontaine et al., "NEOADJUVANT PERCUTANEOUS-4-HYDROXYTAMOXIFEN DECREASES BREAST CANCER CELL PROLIFERATION: A PROSPECTIVE RANDOMIZED IMAGE ANALYSIS STUDY", Analytical Cellular Pathology, vol. 25, no. 5-6 2003, pp. 258-259, XP009030125.		

Examiner Signature: <i>Wegant Cotton</i>	Date Considered: <i>7/2/2006</i>
--	----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.